NPPB and type 2 diabetes mellitus: An analysis of 42 protein biomarkers in the SUMMIT (Surrogate markers for micro-and macro-vascular hard endpoints for innovative diabetes tools) consortium involving individuals with T2DM without apparent CVD and controls, NT-proBNP, high sensitivity troponin T (hs-TnT), and 4 other peptides revealed the ability to increase CV outcome prediction [62].